Lymphoma & Leukaemia Watch 45 - MRD in CLL... what is it and does it matter?

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 35 - Management of TTP after rituximab failure/intolerance

Dr Danny Hsu MBBS FRACP FRCPA

Associate Professor Shaun Fleming discusses CAR T-cell treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)

Associate Professor Shaun Fleming MBBS(Hons) FRACP FRCPA

Head of Myeloid Diseases Service, Clinical Haematology, Alfred Hospital

Conjoint Associate Professor, Australian Centre for Blood Diseases, Monash University

Lymphoma & Leukaemia Watch 44 - Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 43 - Follicular lymphoma into the future

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Myelofibrosis Watch 2 - Momelotinib in myelofibrosis

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

ESMO Clinical practice guideline interim update on the new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

Professor Arnon Kater
Haematologist, Amsterdam University Medical Center

BSH Highlights 2025

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 42 - Odronextamab for DLBCL

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Haematology Watch 34 - T-cell clones of uncertain significance

Dr Danny Hsu MBBS FRACP FRCPA

Professor Michael Dickinson discusses CAR T-Cell Therapy: Axicabtagene Ciloleucel for Second-Line Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Professor Michael Dickinson MBBS, D Med Sc, FRACP, FRCPA

Lymphoma & Leukaemia Watch 41 - Novel approaches in T cell lymphoma

Dr Hannah Hsu BMedSci, MBBS, FRACP, FRCPA

Myelofibrosis Watch 1 - Treatment of Myelofibrosis

Dr Jacinta Perram MBBS(Hons), BA(Psych), BMedSc, MPH, FRACP, FRCPA, ECFMG Cert.

Lymphoma & Leukaemia Watch 40 - AMPLIFYing CLL

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 33 - Targeted anti-cancer agents & VTE

Dr Danny Hsu MBBS FRACP FRCPA

Advancing CAR T-cell therapy in Australia: The Referral Process and Patient Journey

These videos form the educational basis for a Research Review E-Learning Module, intended for Australian Health Professionals. Viewers may watch the videos, complete a short CPD quiz (see link below) and claim the time spent as a CPD activity. For more background information, read the previous Educational Series publication: Advancing CAR T-cell therapy in Australia: collaborative approaches for relapsed/refractory large B-cell lymphoma. We feature Dr Adam Bryant, Associate Professor Andrea Henden and Senior CAR-T cell Clinical Nurse Co-ordinator Cassie Abbott.

The video discussion focuses on the current CAR-T treating centres as at Jan 2025, additional centres may be added after this time.

ASH Highlights 2024 focus on Lymphoma & Leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

ASH CAR-T cell therapy Highlights 2024

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 39 - AN + AD for advanced stage Hodgkin Lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 32 - Update on DOACs: New indications...and limitations

Dr Danny Hsu MBBS FRACP FRCPA

Blood Highlights 2024 - Focus Lymphoma & Leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 38 - Mantle cell lymphoma into the future

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 37 - Treatment of minimal residual disease in acute myeloid leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Professor Michael Dickinson discusses CAR T Cell Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Professor Michael Dickinson MBBS, D Med Sc, FRACP, FRCPA

Lymphoma & Leukaemia Watch 36 - Early stage follicular lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 35 - Deciding on allograft in NPM1 AML

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

EHA Highlights 2024

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 31 - Anticoagulation in cirrhosis ISTH SSC guidance

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 34 - Asciminib in chronic myeloid leukaemia

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 30 - ASCO 2024: Update on key studies in multiple myeloma

Dr Adam Bryant MBBS (Hon) PhD FRACP FRCPA

Haematology Watch 29 - Real world use of TPO-RA for ITP in the UK: TRAIT study

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 33 - 2 new treatments for T cell lymphomas

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 32 - Luspatercept vs epoetin alfa for treatment of anaemia in low risk MDS

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Multiple Myeloma Watch 4 - t(11;14) myeloma have a B-cell like program and acquire numerous changes with resistance to venetoclax

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

ASH Highlights 2023

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 28 - Large B-cell lymphoma (LBOL) investigation & management

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 27 - Elranatamab (anti-BCMA BiTE) for Multiple Myeloma

Professor Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Haematology Watch 26 - Final study report of andexanet alfa for major bleeding with factor Xa inhibitors

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 30 - Allograft prolongs survival in TP53 mutated MDS

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 25 - Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

Dr Adam Bryant MBBS (Hon) PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 29 - Menin inhibitor revumenib in refractory acute leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 24 - Predicting response in ITP

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 27 - Zanubrutinib vs Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukaemia

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 22 - Ruxolitinib is a valid treatment option in polycythaemia vera

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 21 - Risk of relapse in immune TTP and role of anti-CD20 therapy

Dr Danny Hsu MBBS FRACP FRCPA

Multiple Myeloma Watch 3 - NOVEL classes of therapy for relapsed and refractory myeloma; options other than CAR-T cells and bispecific antibodies!

Dr Adam Bryant MBBS (Hon) PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 25 - Bispecific Antibodies in B-Cell Lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Multiple Myeloma Watch 2 - KCD based therapy versus AuSCT in myeloma

Professor Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Haematology Watch 19 - Non-malignant Haematology Highlights-Blood 2022

Dr Monique Menzies Wojtowicz BAppSc(Pthy) MBBS(Hons) FRACP, FRCPA

Multiple Myeloma Watch 1 - Myeloma Transplant and CAR-T guidelines

Professor Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 23 - Ph+ ALL; Decision making regarding allograft in CR1

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 22 - Updates in diffuse large B cell Lymphoma

Dr Shafqat Inam MBBS MMed FRACP FRCPA

Haematology Watch 18 - New Modalities for the management of ITP - ATRA and BTKi

Professor Harshal Nandurkar MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 21 - Updates in peripheral T cell lymphoma

Dr Shafqat Inam MBBS MMed FRACP FRCPA

Lymphoma & Leukaemia Watch 20 - POLARIX Study - A New Standard of Care in DLBCL?

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Haematology Watch 16 - Advancing treatment options for Paroxysmal Nocturnal Haemoglobinuria

Professor Harshal Nandurkar MBBS PhD FRACP

Lymphoma & Leukaemia Watch 18 - A Randomized Phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 17- Development of Second Generation BTKi in the Treatment of Lymphoid Cancers Part 2

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Haematology Watch 14 - ASH 2021 Abstracts Part 2; ITP

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 15 - SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab in Patients with Treatment-Naive CLL/SLL

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Lymphoma & Leukaemia Watch 14 - Recent local and international studies assessing pediatric ALL therapy adults <40y

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 13 - ASH 2021 Myeloid Disorders Abstracts Part 2

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Thrombosis & Haemostasis Watch 1 - Targeting coagulation factor XI for Thromboprophylaxis

Professor Harshal Nandurkar MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 12 - Advanced Stage Hodgkin Lymphoma: a case based approach

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Haematology Watch 11 - ASH 2021 Myeloid Disorders Abstracts

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology WATCH 10 BMT vs no BMT in Elderly MDS: A Biological Assignment Trial

Dr Bart Getta MBBS (HONS 1) (UNSW) GCert CLIN EPI (USYD) ECFMG FRACP FRCPA

Treatment approach and considerations in non-transplant eligible ndMM

Professor Simon Harrison MBBS, MRCP (UK), FRCPath (UK), FRACP, PhD

Haematology Watch 9 - Relapsed/Refractory Hodgkin Lymphoma: A Case Based Approach

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Haematology Watch 8 - Vaccine - Induced Immune Thrombotic Thrombocytopenia

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 10 - New evidence to aid decision making in the treatment of older patients with AML (Part 1)

Dr Bartlomiej Getta MBBS (HONS 1) (UNSW) GRAD CERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 7 - DOAC in Obese Patients

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 7 - Updates in secondary CNS and limited stage diffuse large B cell Lymphoma

Dr Pietro Di Ciaccio BA LLB (Hons) MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 6 - Two updates in Burkitt & HGBCL

Dr Pietro Di Ciaccio BA LLB (Hons) MBBS FRACP FRCPA

Haematology Watch 6 - TPO receptor agonists in Pregnancy for ITP

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 5 - Polatuzumab Vedotin & Relapsed/Refractory Diffuse Large B-cell Lymphoma

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Haematology Watch 4 featuring a Q&A discussion Series 2

Dr Maya Latimer, Consultant Haematologist at the Canberra Region Cancer Centre, CRCC, the Canberra Hospital, ACT interviewing Professor Alessandra Ferrajoli, academic haematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson.